GAPNA Conference Summary: Pharmacology Update

Byrd features the Gerontological Advanced Practice Nurses Association's annual pharmacology update on medications for use in the older population with an in-depth discussion on anticoagulation therapy, select non-molecular entities for 2011-2012, Federal Drug Administration's safety concer...

Full description

Saved in:
Bibliographic Details
Published inGeriatric nursing (New York) Vol. 33; no. 6; p. 501
Main Author Byrd, Lisa
Format Journal Article
LanguageEnglish
Published New York Elsevier Science Ltd 01.11.2012
Subjects
Advanced practice nurses
Alzheimer's disease
Conferences
Drug dosages
Drug therapy
Drugs
Geriatrics
Insight
Muscles
Older people
Pharmacology
Online AccessGet full text

Cover

More Information
Summary:Byrd features the Gerontological Advanced Practice Nurses Association's annual pharmacology update on medications for use in the older population with an in-depth discussion on anticoagulation therapy, select non-molecular entities for 2011-2012, Federal Drug Administration's safety concerns, and some insights on medications for use in individuals with Alzheimer's disease. One update is about the overactive bladder (OAB) medication Mirabegron. Due to be released by the end of the year 2012, Mirabegron is the first and only beta-3 adrenergic agonist indicated for the treatment of overactive bladder OAB. It works by relaxing the detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle by activation of beta-3 adrenergic receptors which increases bladder capacity. Mirabegron is recommended to be started at dosage of 25 mg once daily with or without food and is usually effective within eight weeks.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0197-4572
1528-3984